Posted inBiotechnology
Blueprint ends work on clinical-stage CDK2 inhibitor but pushes on in breast cancer
Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with similar preclinical breast…








